

patients included in the jugular access series would be implanted with a permanent pacemaker.<sup>2</sup>

- 3 **Infections and thromboembolisms:** it is well-known that femoral electrodes are associated with local infection and sepsis, as well as deep vein thrombosis and pulmonary embolism. Authors report on the limited appearance of infections and lack of thrombotic events. Providing information on whether infectious or thromboembolic prophylaxis was used could shed light on how to understand the study much better.<sup>4,5</sup>
- 4 **Delay until definitive pacemaker implantation:** finally, we would like to say that most complications increase the longer the time until definitive pacemaker implantation. Although the cause of bradyarrhythmia can be reversible, most patients will end up being implanted with a definitive pacemaker. In this study, 32 out of a total of 35 patients (91.4%) received a permanent pacemaker with a mean time elapsed until implantation of  $4.9 \pm 4.6$  days. Although the authors say that it is a short waiting time, minimizing these times—in case of foreseeable nonreversible bradyarrhythmias—could lead to fewer complications by just generalizing these procedures.

In conclusion, we agree with the authors on the utility of using active-fixation electrodes to prevent electrode displacement. However, based on the information currently available, we believe that ultrasound-guided jugular puncture and the early implantation of definitive devices should be considered the strategy of choice.

## References

- Keituaqwa Yáñez I, Navarro Martínez J, García Valiente M, Rodríguez González FJ, Nicolás Franco S. Outcomes of temporary pacing via transfemoral externalize active fixation leads. *Med Intensiva*. 2021;S0210-5691(20):30346-6, <http://dx.doi.org/10.1016/j.medin.2020.11.005>. Online ahead of print.
- Suarez K, Banchs JE. A review of temporary permanent pacemakers and a comparison with conventional temporary pacemakers. *J Innov Card Rhythm Manag*. 2019;10:3652–61.
- Ferri LA, Farina A, Lenatti L, Ruffa F, Tiberti G, Piatti L, et al. Emergent transvenous cardiac pacing using ultrasound guidance: a prospective study versus the standard fluoroscopy-guided procedure. *Eur Heart J Acute Cardiovasc Care*. 2016;5:125–9.
- Peters G, Saborowski F, Locci R, et al. Investigations on staphylococcal infection of transvenous endocardial pacemaker electrodes. *Am Heart J*. 1984;108:359–65.
- Nolewajka AJ, Goddard MD, Brown TC. Temporary transvenous pacing and femoral vein thrombosis. *Circulation*. 1980;62:646–50.

N. Pueyo-Balsells, P. Irigaray,  
I. Calaf, D. Fernández-Rodríguez\*

*Hospital Universitari Arnau de Vilanova de Lleida, IRBLLeida (Institut de Recerca Biomèdica de Lleida), Lleida, Spain*

\* Corresponding author.

E-mail address: [dfernandez.lleida.ics@gencat.cat](mailto:dfernandez.lleida.ics@gencat.cat) (D. Fernández-Rodríguez).

2173-5727/ © 2022 Published by Elsevier España, S.L.U.

## Dexametasona en COVID-19: ¿un medicamento para todos?



### Dexamethasone in COVID-19: does one drug fit all?

Dear Editor,

The COVID-19 pandemic challenged clinicians worldwide to treat a new and unknown disease. With more than 95 million confirmed cases since its beginning<sup>1</sup>, a lot of effort has been made to identify the best possible treatments.

The RECOVERY trial<sup>2</sup> provides strong evidence in favor of the administration of 6 mg of dexamethasone for ten days once a day in COVID-19 patients, if requiring at least oxygen supplementation (the incidence of death in the dexamethasone group compared to the usual care group was 23.3% vs 26.2% for patients receiving oxygen, and 29.3% vs 41.4% for patients under mechanical ventilation at the time of randomization). This finding changed the WHO therapeutic guidelines for patients with COVID-19<sup>3</sup> and triggered into clinicians the automatic binomial prescription: oxygen therapy-dexamethasone. In the current pandemic era, where everyone is searching for the magic bullet, and no clear evidence is available on any therapeutic agent capable to reduce mortality, having this option with such a familiar drug gave back to clinicians the feeling of having at least a weapon.

The trial findings were confirmed also in a recent meta-analysis<sup>4</sup> including more than seven thousand patients: overall mortality was significantly lower in the corticosteroids group (26% vs 28%, relative risk {RR} = 0.89 [95% confidence interval {CI} 0.82-0.96],  $p=0.003$ ). However, for COVID-19 patients not requiring oxygen the meta-analysis suggested an increase in mortality in patients receiving corticosteroids (17% vs 13%,  $RR = 1.23$  [95% CI 1.00-1.62],  $p = 0.05$ ).

The rationale for the use of dexamethasone is the mitigation of the inflammatory organ injury that may occur during SARS-CoV-2 infection. In the RECOVERY Trial the benefit of dexamethasone was indeed clear when inflammatory lung damage was more likely to be common, that is supposed to be in those patients treated “more than 7 days after symptom onset”. However, as mentioned by the authors of the trial, only a subgroup of severe COVID-19 patients showed significant elevation in inflammatory biomarkers (such as C-reactive protein and ferritin), and unfortunately the “inflammatory lung damage” was advocated but not assessed.

Beside the desired anti-inflammatory effect, dexamethasone is also known for its immunosuppressive properties, that can lower resistance to bacterial and viral infections through a cell-mediated mechanism. Although steroids were recently found not to affect time to negativization of nasopharyngeal swab in a cohort of 280 Italian patients<sup>5</sup>, the development of secondary opportunistic infections certainly remains a major issue, affecting patients’ outcome.

Furthermore, as well as corticosteroids increase mortality in patients not requiring oxygen therapy<sup>4</sup>, it is reasonable to think

that their effect among patients requiring low flow oxygen could be mixed. As in a previous study<sup>6</sup> that identified two different subphenotypes of acute respiratory distress syndrome, one of which was categorised by more severe inflammation, it is likely that also in COVID-19 patients different inflammatory patterns may occur. In support to this previous finding, a recent review and meta-analysis of COVID-19 studies focused on the role of cytokines and inflammatory biomarkers and found different mean levels of C-reactive protein between severe and critical COVID-19 patients (55.9 µg/mL [CI 23.1-88.8 µg/mL

Beyond the initial enthusiasm after the trial results, leading to an almost indiscriminate adoption of dexamethasone in COVID-19 patients, we suggest that a more personalized prescription would lead to further improvements in patients' outcome. We think that, beside avoiding corticosteroids for patients not on oxygen, COVID-19 patients requiring oxygen should be screened for high or normal inflammatory biomarkers thresholds. Furthermore, for those patients who may benefit from corticosteroid treatment it is reasonable to investigate whether a higher or a lower dose of dexamethasone is most beneficial, and a clinical trial is currently ongoing randomising patients with severe hypoxia to receive either 6 or 12 mg of dexamethasone.<sup>7</sup>

This would serve to target inflammation only in those patients who would probably benefit from its modulation, while removing the burden of corticosteroids side effects in those patients without an inflammatory pattern who would probably not benefit from this therapy.

## Authors' contributions

All the authors have substantially contributed to the conception of the work, and to the drafting or revision; all the authors have approved the final version and agree to be accountable for all the aspects of the work.

## Conflicto de intereses

Los autores declaran no tener ningún conflicto de intereses.

## Bibliografía

1. WHO Coronavirus Disease (COVID-19) Dashboard, <https://covid19.who.int>. [accessed 10 February 2021].

2. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med.* 2021;384:693-704, <https://doi.org/10.1056/NEJMoa2021436>. Epub Jul 17 2020.
3. Therapeutic Management | COVID-19 Treatment Guidelines (nih.gov) <https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/>. [accessed 10 February 2021].
4. Pasin L, Navalesi P, Zangrillo A, Kuzovlev A, Likhvantsev V, Hajjar LA, et al. Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials. *J Cardiothorac Vasc Anesth.* 2021 Feb;35:578-84, <http://dx.doi.org/10.1053/j.jvca.2020.11.057>.
5. Spagnuolo V, Guffanti M, Galli L, Poli A, Rovere Querini P, Ripa M, et al., COVID-BioB study group. Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. *Sci Rep.* 2020 Dec 4;10:21291, <http://dx.doi.org/10.1038/s41598-020-78039-1>.
6. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA. NHLBI ARDS Network Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. *Lancet Respir Med.* 2014 Aug;2:611-20, [http://dx.doi.org/10.1016/S2213-2600\(14\)70097-9](http://dx.doi.org/10.1016/S2213-2600(14)70097-9). Epub May 19 2014.
7. Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia (COVIDSTERIOD2). <https://clinicaltrials.gov/ct2/show/NCT04509973>.

A. Zangrillo<sup>a,b</sup>, G. Landoni<sup>a,b,\*</sup>, G. Monti<sup>b</sup>,  
A.G. Yavorovskiy<sup>c</sup> y M. Baiardo Redaelli<sup>b</sup>

<sup>a</sup> *Faculty of Medicine, Vita-Salute San Raffaele University, Milan, Italy*

<sup>b</sup> *Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy*

<sup>c</sup> *Department of Anesthesiology and Intensive Care, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian, Moscow, Russia*

\* Autor para correspondencia.

Correo electrónico: [landoni.giovanni@hsr.it](mailto:landoni.giovanni@hsr.it) (G. Landoni).

0210-5691/ © 2021 Elsevier España, S.L.U. y SEMICYUC. Todos los derechos reservados.